about our company


At CardioFocus, we specialize in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation.

Our focused dedication on advancing cardiac ablation treatments has resulted in the ground-breaking HeartLight® Endoscopic Ablation System, integrating important new features into a never-before-seen platform as advanced as it is intuitive. And our ongoing research is taking laser ablation therapies to exciting new places.


The HeartLight Endoscopic Ablation System provides physicians with a number of unique and valuable new capabilities. Now, they can directly visualize anatomies intra-procedure, precisely target the application of laser energy, and deliver durable pulmonary vein isolation.



FEBRUARY 21, 2020


FEBRUARY 28-29, 2020



    Executive Chairman


    Mr. LaViolette has served as the Executive Chairman of CardioFocus since 2013, bringing more than 35 years of global medical technology management experience. Previously, he served as the Chief Operating Officer of Boston Scientific Corporation (BSC), an $8 billion medical device leader. During his 15 years at BSC, he also held positions including: Group President Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International during a period in which revenues grew 20 times. Mr. LaViolette integrated two dozen acquisitions and led extensive product development, operations and worldwide commercial organizations. He previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Covidien).

    In addition to the Executive Chairman role at CardioFocus, Mr. LaViolette is the Managing Partner and Chief Operating Officer at SV Health Investors, serves as the Vice Chairman of the Innovation Advisory Board for the Partners Health System, and is the Chairman for the Medical Device Manufacturers Association.

    Chief Executive Officer


    Mr. Barrett joined CardioFocus in 2002 and currently serves as Chief Executive Officer (CEO), leveraging over 30 years of medical device industry experience into the role of CEO. He joined CardioFocus in 2002, and during his more than 15 years with the company has held roles of increasing responsibility from Vice President through to President and COO.

    Prior to joining CardioFocus, Mr. Barrett was Vice President of Clinical Operations at Cyberkinetics Neurotechnology Systems, Inc., a public medical device company that achieved first-in-man success in novel, implantable brain-computer interfaces. He also served at Cyberonics as the Vice President, Business and Technology Development. Previously, Mr. Barrett held positions in business development, clinical & regulatory affairs, and quality auditing at Biofield Corporation, Dornier Medical Systems, and Bausch & Lomb.

    Mr. Barrett is a co-inventor on numerous issued and pending patent applications. From 2010-2013 he served as the industry representative on the Food and Drug Administration’s (FDA) Circulatory Systems Device Advisory Panel. He received bachelor’s degrees in chemical engineering and chemistry from Syracuse University and a Master of Business Administration from Kennesaw University in Atlanta.



    Mr. Bouknight joined CardioFocus in 2016 and serves as its President. He has substantial experience launching novel cardiac medical technologies on a global basis. Prior to joining CardioFocus, Mr. Bouknight held the role of Vice President of Sales and Marketing for Cardiac Dimensions, an early-stage cardiovascular company with an innovative mitral valve repair system. Prior to Cardiac Dimensions, he led the highly successful launch of the HeartMate II® Left Ventricular Assist System® at Thoratec Corporation, where he served in the role of Business Unit Director.

    Mr. Bouknight began his cardiovascular medical technology career at Guidant Corporation, working directly with electrophysiologists as a Certified Cardiac Device Specialist (CCDS). He holds an MBA from Harvard Business School and Bachelor’s degrees in Supply Chain Management, International Relations, and German from Michigan State University.

    Vice President, Program Management


    Ms. Anderson joined CardioFocus in 2018 as Vice President, Program Management.  She brings over 20 years of experience in the medical device industry in a variety of functional areas including product development, program management, and continuous improvement.  She was previously Director of Program Management, Global Product Development at Haemonetics, where she led a team of project and program managers responsible for the successful management of a global portfolio of product development programs.  Ms. Anderson also held positions at OmniGuide Surgical and Philips Medical.  She received a BS in Mechanical Engineering from MIT and a Master of Engineering in Mechanical Engineering from Carnegie Mellon University.

    Vice President, Operations


    Mr. Casey has over 25 years of domestic and international leadership experience in the Medical device and Capital equipment industries. He has extensive experience with Supply Chain development, Contract Manufacturing, production transfer and new facility start up.   Past roles have included V.P of Manufacturing and Supply Chain for Ivenix. a start-up medical device company developing a large volume infusion pump, V.P. of Global Manufacturing for Optos and Executive Director of Operations for Olympus – GyrusACMI.  He received a bachelor’s degree in Mechanical Engineering with a Minor in Industrial Engineering from the University of Dayton. Additionally, he has multiple certifications in Supply Chain Management including, CPIM Production and Inventory Management and CSCP, Certified Supply Chain Professional.  He also has extensive Lean Manufacturing experience and has a Six Sigma Greenbelt.

    Vice President, Regulatory Affairs & Quality Assurance


    Mr. Christianson joined CardioFocus in October 2009, bringing over 10 years of experience in quality assurance and operations experience in medical devices and the defense industry. He was previously Director of Quality Assurance and Regulatory Affairs at Concordia Medical, a contract manufacturer of medical devices and tissue engineering scaffolds. Mr. Christianson has held positions at Boston Scientific, Genzyme Biosurgery, and Johnson & Johnson. He received a Bachelor’s degree in Industrial Engineering from the University of Arizona, a Master’s degree in Industrial Engineering from Texas A&M University, and an MBA from the University of Massachusetts-Dartmouth.

    Vice President, Finance & Administration


    Scott Fletcher joined CardioFocus in February 2017 bringing over 15 years of experience in the medical device industry.  Prior to joining CardioFocus Mr. Fletcher served as Vice President Finance and Administration at Holmed (later a part of NN Inc.), a firm specializing in the design and manufacturer of spine and orthopedic surgical instrumentation. At Holmed Mr. Fletcher led the finance, accounting, human resources and IT departments.  Mr. Fletcher previously held positions as Director of Finance for Precision Engineered Products, an orthopedic medical device manufacturer and as Site Controller for SMTC, an electromechanical manufacturing company focused on the technology sector.  He received a BS in Business Administration from the University of Vermont in 1998.

    Vice President, US Sales


    Mr. MacDonell joined CardioFocus in August 2019 as Vice President of US Sales.  He brings 25 years of experience in the medical device industry, including electrophysiology, cardiac rhythm management, heart failure, and diagnostics.  Mr. MacDonell spent the majority of his career with St. Jude Medical where he most recently held the positions of Vice President of Sales and Vice President of Strategy and Disease Management.  In these roles, he led teams responsible for launching several innovative technologies in electrophysiology, particularly in arrhythmia identification and therapy.  Mr. MacDonell has also served as Vice President of Sales for early to mid-stage start-ups in the cardiac diagnostic space, helping to build and execute successful commercialization in the US market.  He holds a BS in Biomedical Engineering from Texas A&M University and an MBA from Arizona State University.

    Vice President, Engineering


    Mr. Melsky joined the CardioFocus team in 2002 as Vice President of Engineering, bringing with him over 30 years of leadership experience in medical device design and development. He was previously Director of Mechanical Engineering for Infusaid corporation, the first company to receive IDE approval for an implantable drug pump. Mr. Melsky was also a co-founder of Therex corporation, where he developed a next-generation implantable drug infusion pump now marketed by Johnson and Johnson. Prior to joining CardioFocus, Mr. Melsky was Director of Engineering for Act Medical, now part of Accellent, Inc., where he headed a team of forty engineers and technicians developing a range of devices for minimally-invasive catheter-based procedures. He holds numerous patents in medical device designs, and a Bachelor’s and Master’s degree in mechanical engineering from M.I.T.

    Vice President, Global Marketing & Education


    Ms. Whittaker joined CardioFocus in 2011, bringing over 20 years of professional experience in the healthcare and medical device industries. She was previously Business Development Manager at Bard Electrophysiology, as well as a Clinical Specialist for Medtronic Cardiac Rhythm Management.  Ms. Whittaker is a registered nurse (RN) certified by the International Board of Heart Rhythm Examiners as a Cardiac Device Specialist (CCDS) and as an EP Specialist (CEPS). Early in her career, Ms. Whittaker spent over 10 years as a critical care nurse in the Cardiac Surgical Intensive Care Unit at Massachusetts General Hospital and Electrophysiology Lab at Brigham and Women’s Hospital. Ms. Whittaker has a Bachelor’s degree in Economics and Finance from the University of Connecticut, and an MBA with a concentration in Finance from Suffolk University.

    Senior Director, Clinical Affairs


    Ms. Hausmann joined CardioFocus in 2012 with over 20 years of experience in Clinical Affairs within the medical device industry. Her areas of expertise include early strategic planning; operations; safety; and data analysis and management for feasibility, IDE, and post-market clinical trials. Prior to CardioFocus, she held management positions at Augmenix, Inc., Innovative Spinal Technologies, Inc., OmniSonics Medical Technologies, Inc., and NxStage Medical, Inc. She has worked on products in a variety of therapeutic areas including cardiovascular, peripheral vascular, neurovascular, spine, radiation oncology, urology, and ESRD. Early in her career, Ms. Hausmann held positions of increasing scope and responsibility over a period of 11 years at Boston Scientific Corporation. Ms. Hausmann received a Bachelor’s degree from the University of California at Davis and earned her Master’s in Public Health with a concentration in biostatistics and epidemiology at Boston University.

    Managing Director, International


    Mr. Jameson joined CardioFocus in 2017 as Managing Director, International with over 25 years’ experience within the cardiology and cardiac electrophysiology medical device fields. Prior to CardioFocus, Mr. Jameson held several leadership roles within Europe as Marketing Director, EMEA for St Jude Medical and Abbott based in Brussels, Belgium and European Sales Director, Endosense SA located in Geneva, Switzerland where he led the first successful commercial introduction of the TactiCathTM contact force sensing technology for radiofrequency ablation that has since become a gold standard in clinical practice. For 10 years with Biosense Webster, a Johnson & Johnson company, Mr Jameson provided key leadership within Europe to the successful and rapid expansion of cardiac electrophysiology technologies including market game changers such as irrigated ablation and the CartoÒ electro-anatomical mapping system, together with novel concepts such as the application of Six Sigma process improvement to healthcare.


    Mr. Jameson began his career as a qualified Cardiac Physiologist, attaining head of department level before transitioning into the medical device industry and holds a Bachelor’s Degree in Pure & Applied Mathematics.


  • Omar Amirana, MD

    Dr. Amirana leads the strategic direction and development of the Life Sciences portfolio for Allied Minds (LSE: ALM.L), a publicly traded company focused on venture creation and commercialization. In addition to serving as CEO of two Allied Minds portfolio companies, he also contributes to the Allied Minds joint ventures with Bristol-Myers Squibb and General Electric. Dr. Amirana previously served as Partner at Oxford Bioscience Partners, a Boston-based venture capital firm with ~$1B under management. There he led the Series A investment in nFocus Neuromedical (brain aneurysm therapy; acquired by Covidien), served on numerous boards and participated in numerous financings. He has also served on the board of the Ignition Awards Committee at BU and the Coulter Committee at Columbia University. He has co-founded or held varying senior executive roles in four startups and served as VP of Business Development at St Jude Medical (now Abbott; NYSE:ABT).

  • Chris Kroeger, MD

    Dr. Kroeger served as the President and Chief Executive Officer of Cardioxyl Pharmaceuticals from 2008 until its acquistion by Bristol Myers Squibb (BMY) in December of 2015, and served on the Company’s Board of Directors since 2006. Dr. Kroeger advised Cardioxyl through the initial stages of company formation, and then led the company through all phases of development from discovery through to late stage clinical studies of both CXL-1020 and CXL-1427, Cardioxyl’s lead assets in acute decompensated heart failure. He built and led a highly effective and efficient scientific, clinical and operations team that produced three IND candidates and successfully executed six Phase 1 and Phase 2 clinical studies. Dr. Kroeger also effectively financed the company’s activities, attracting over $80MM of private investment from multiple top tier venture capital firms. During his tenure, he negotiated numerous licenses and partnerships and engineered the ultimate sale of Cardioxyl to BMS for $2.1 billion in total consideration.

    Prior to joining Cardioxyl, Dr. Kroeger led the biopharmaceutical and medical device investing efforts for the Aurora Funds, a venture capital firm that he joined in 2003 and where he remains a Partner. He has been involved in the board governance and/or strategic oversight of fifteen venture backed drug and medical device companies and currently sits on the boards of CardioFocus and Cantex Pharmaceuticals. Of the five early stage companies in which Dr. Kroeger led direct investments for Aurora, two have FDA approved PMA medical devices, and two have completed successful Phase 2 clinical development of pharmaceuticals in areas of significant unmet medical need. Dr. Kroeger previously trained in General Surgery at Brigham and Women’s Hospital in Boston, part of the Harvard Medical System. He earned his MBA from Harvard Business School, his M.D. from Stanford University School of Medicine, and his BS from Harvard University.

  • Charles Larsen

    Mr. Larsen is a co-founder and Managing Director of Accuitive Medical Ventures. He brings over 35 years of operating experience, as well as expansive technical understanding and experience in the medical device industry. Mr. Larsen was a co-founder of Novoste Corporation with Tom Weldon where his efforts as a director and executive were critical to its ultimate success. Mr. Larsen also co-founded The Innovation Factory and serves as its Vice Chairman. Through his role at The Innovation Factory, Mr. Larsen has co-founded numerous companies including: Acufocus, AqueSys, Halscion, LipoSonix, Neuronetics and Sebacia. He holds over 30 issued U.S. and international patents on medical devices.

  • Paul LaViolette

    Mr. LaViolette is the Managing Partner and Chief Operating Officer at SV Health Investors, bringing more than 35 years of global medical technology management experience. Previously, he served as the Chief Operating Officer of Boston Scientific Corporation (BSC), an $8 billion medical device leader. During his 15 years at BSC, he also held positions including: Group President Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International during a period in which revenues grew 20 times. Mr. LaViolette integrated two dozen acquisitions and led extensive product development, operations and worldwide commercial organizations. He previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Covidien).

  • Greg Madden

    Mr. Madden is a Principal for SV Health Investors, a leading healthcare and life sciences venture capital and growth equity firm.  He joined the firm in 2002 and focuses on medical device and healthcare services investments.  He is actively engaged in the financing, strategy, operations, and acquisitions of portfolio companies.

    Prior to joining SV, Mr. Madden worked at Testa, Hurwitz & Thibeault, in the Business Practice, Emerging Technology, and Private Equity groups, supporting both venture capital funds and venture backed companies in business formations and financings, mergers and acquisitions, and venture capital fundraising.

  • Bruce Robertson, PhD

    As Managing Director of H.I.G. BioHealth Partners, Dr. Robertson focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. Dr. Robertson has been active in the life sciences sector for more than 20 years. Prior to joining H.I.G., he served most recently as Managing Director at Toucan Capital, a venture capital fund focusing on life science investments. While at Toucan, Dr. Robertson invested in leading drug and device companies throughout the U.S. Prior to Toucan, he was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his private equity career, Dr. Robertson was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN’s partnering and M&A strategies.

  • Patrick Wethington

    Mr. Wethington serves as the President and Chief Executive Officer of Stimdia Medical, Inc, a privately-held company which is developing products to treat patients with ventilator induced diaphragmatic dysfunction (“VIDD”).  He was previously the Chief Executive Officer and President of CardioInsight Technologies Inc. (acquired by Medtronic) as well as the Chief Executive Officer and President of Hemosphere, Inc. (acquired by CryoLife).  Mr. Wethington has more than 25 years of cross functional medical device experience in the cardiovascular industry, including leadership roles at Guidant, Endocardial Solutions (acquired by St. Jude Medical), St. Jude Medical Inc. and CHF Solutions, Inc. (acquired by Gambro).


  • Accuitive Medical Ventures

    Accuitive Medical Ventures is a venture capital firm with committed capital of $230 million. A market-driven firm looking for revolutionary medical device technology investment opportunities, Accuitive has offices in Atlanta, GA and Amelia Island, FL.

  • Aurora Funds

    Aurora Funds is a family of venture capital funds committed to providing resources to help early stage healthcare and information technology companies reach their full potential. Aurora’s investment team has the experience, strategic relationships and capital to help companies accelerate their growth and gain a strong competitive advantage in their market space. Since its founding in 1994, Aurora has invested in over 60 portfolio companies, resulting in five IPOs and eight M&A transactions.

  • BioMed Ventures

    BioMed Ventures is the strategic investment arm of BioMed Realty. Acquired by Blackstone in 2016, BioMed Realty is the leading provider of real estate solutions to the life science industry – providing leasing, development, construction, redevelopment, acquisition, financing and property management to clients in the United States and United Kingdom, with over 12 million square feet of rentable space worldwide.

  • Fletcher Spaght Ventures

    Fletcher Spaght Ventures, (FSV) is a balanced-stage venture capital firm investing in high growth opportunities in healthcare/life sciences and related information technology companies. FSV was established in 2001 by Fletcher Spaght, Inc. (FSI), a strategy consulting firm founded in 1983. The FSI:FSV collaboration provides key differentiation from other venture capital firms and allows for significant advantages in deal sourcing and investing.

  • HIG BioHealth Partners

    With $400 million in assets under management, H.I.G. BioHealth Partners invests in a broad range of healthcare companies across multiple sectors and stages of development. Its seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. It invests in companies developing novel products for significant unmet medical needs.

  • Industry Ventures

    Industry Ventures is a leading investment firm that focuses on venture capital. The firm has three investment strategies: secondary investments, primary fund of funds investments and direct co-investments. Founded in 2000, the firm manages over $3 billion of institutional capital and is headquartered in San Francisco with an office in Washington, D.C.

  • KBL Healthcare Ventures

    KBL brings a team of investment professionals with prior experiences as senior executives, clinical practitioners and venture capitalists. While it is capable of bringing managerial and technical expertise to an emerging company, it is also able to draw upon a rich network of contacts across multiple disciplines to foster the growth and development of its portfolio companies. KBL prides itself on developing lasting relationships with its entrepreneurs and looks to cultivate a professionally and personally rewarding experience for all involved.

  • Kestrel Management

    Kestrel Management invests in early stage healthcare companies. Investments other than CardioFocus include Health Dialog (disease management), PHT Corp. (Clinical trial support), Iora Healthcare (patient centric primary care), and Constant Therapy (digital solutions to brain injury). Kestrel typically invests at the pre-revenue stage and partners with both angels and venture capital firms.

  • SightLine Partners

    Sightline Partners is an alternative investment manager providing custom equity financing for differentiated, growth-stage healthcare companies. It invests in select, high-potential healthcare companies to unlock value others can’t. Through custom financing solutions and active management, Sightline Partners helps propel these companies to the exit and realize consistent performance for its investors.

  • SV Health Investors

    SV Health Investors is a leading healthcare and life sciences venture capital and growth equity firm. Its goal is to transform healthcare – one investment at a time – by supporting the entrepreneurs who create and build breakthrough companies and treatments. With over $2 billion in capital under management in seven private healthcare funds, a 20-year track record in the US and Europe and offices in Boston, San Francisco and London, SV Health Investors drives game-changing innovation.


There are presently no open positions.